Most GLP-1 users are Vitamin D deficient before they start — 4 reasons to supplement

Semaglutide, tirzepatide, liraglutide — GLP-1 receptor agonists produce weight loss no previous drug class has matched. They also produce bone loss, muscle loss, and a nutritional shortfall in which vitamin D is the single most common deficiency to appear.

Most users do not start from a healthy level. In a cohort of 5,384 type-2 diabetics beginning semaglutide, median baseline 25(OH)D was 19.3 ng/mL, and 1,757 of them — roughly one in three — were already below 15 ng/mL before the first injection.

It gets worse from there. In claims data covering 461,382 US adults who had no prior nutritional deficiency diagnosis, new vitamin D deficiency was recorded in 7.5% by 6 months and 13.6% by 12 months — the most common deficiency of any kind. Any nutritional deficiency: ~13% at 6 months, 22% at 12 months. A narrative review pooling six studies (480,825 adults) reached the same conclusion: vitamin D leads the list.

Note that 13.6% is a floor, not a prevalence. It counts only people who got tested and coded. The real number is far higher.

Why it happens — three mechanisms at once

Reduced intake. In a dietary analysis of 69 GLP-1 users, most failed to meet recommended intakes for vitamin D, iron, calcium and protein.
Reduced fat intake. Vitamin D is fat-soluble. Eating far less fat means absorbing far less vitamin D.
Delayed gastric emptying and altered absorption. The same properties that make the drugs work impair fat-soluble vitamin uptake.

The mechanism behind all four reasons below: people on GLP-1 move less

A large-scale tracking trial (June 2026) disproved the assumption that weight loss triggers more activity. On GLP-1 therapy, daily step counts fell from 5,047 to 4,487, and moderate-to-vigorous activity fell from 28 minutes/day to 22.

Less mechanical loading → bone loss. Less use → muscle loss. Less muscle and less activity → easier regain when the drug stops. One mechanism, four consequences.

1) Probably lose less muscle if you increase Vitamin D level

This is the largest and best-quantified harm.

The Lancet (Nov 2024) reports that fat-free mass losses with GLP-1 receptor agonists run 25% to 39% of total weight lost over 36–72 weeks. Non-pharmacological caloric restriction, at smaller magnitudes of loss, produces 10–30%. On an annual basis the decline is several times what aging alone would cause — roughly 0.8% per year from ages 40 to 70.

Importantly, the Lancet authors attribute this largely to the magnitude of weight loss rather than to an independent drug effect — while noting the hypothesis still needs testing. That matters here: it means evidence from ordinary weight loss in obese people applies.

And there, vitamin D has a randomized trial behind it. Weight loss includes muscle loss unless you add vitamin D, whey and leucine (RCT, Feb 2015) — since cited in work on preserving muscle during weight loss, pre-bariatric prehabilitation, and sarcopenia formulas.

What this does NOT show: the 2015 RCT tested three components together. Vitamin D alone was not isolated, and the whey and leucine may be doing most of the work. Also, muscle function may hold up better than muscle mass — the SEMALEAN study (n=106) found lean mass dropped about 3 kg by 7 months then stabilized, while grip strength actually rose 4.5 kg and sarcopenic obesity fell from 49% to 33%.

2) Likely lose less bone if you increase Vitamin D level

A 2024 phase-2 randomized controlled trial found that 52 weeks of weekly semaglutide reduced hip BMD by 2.6% and lumbar spine by 2.1% versus placebo, with bone resorption up and no compensating increase in formation.

A retrospective DXA series (n=255) found declines at every site — spine −1.6%, femoral neck −1.8%, total hip −2.8% — with hip loss tracking the amount of weight lost (r = 0.35). Thirteen percent sustained a new fracture.

The vitamin D connection is mechanistic and randomized. Shapses 2013 (82 postmenopausal women, double-blind, placebo-controlled) showed that weight loss decreases true fractional calcium absorption, and vitamin D increases it. Losing weight makes you worse at absorbing calcium; vitamin D corrects exactly that defect.

What this does NOT show: a matched-control version of the n=255 study found similar BMD declines in non-users, suggesting the loss is driven by weight reduction and aging rather than the drug itself. And Shapses concluded that at a calcium intake of 1.2 g/day, either 400 or 2,500 IU/day was sufficient to maintain calcium balance — this is an argument for adequacy, not for megadosing.

3) Probably lose more fat if you increase Vitamin D level

A 12-week RCT in overweight adults with very low calcium intake found calcium plus vitamin D3 produced greater fat mass loss (−2.8 vs −1.8 kg, p=0.02) and greater visceral fat reduction — with no significant difference in body weight. Fat went down; the scale did not distinguish the groups.

In GLP-1 users specifically, the 5,384-patient semaglutide cohort found a dose-response: compared with those below 15 ng/mL, patients at 15–25 ng/mL lost an additional 1.02 BMI units over 12 months and those above 25 ng/mL lost 1.29 more (both p<0.0001). HbA1c also improved, though trivially (−0.08 to −0.10%).

See also [Weight loss and Vitamin D — many studies] for repletion trials in obese people generally.

What this does NOT show: the semaglutide cohort measured baseline status, not supplementation — and the higher-D patients were older, wealthier, and less obese to begin with. Meta-analyses of vitamin D supplementation for weight loss have repeatedly found limited evidence of a causal effect. The likely reconciliation is a threshold effect: women who actually reached replete status lost more weight and improved body composition more than those who supplemented without reaching it. Pooling responders with non-responders washes the signal out.

4) Should regain less weight after stopping GLP-1 if you increase Vitamin D level

Most people stop. In a cohort of 125,475 obese patients, 46.5% of those with T2DM and 64.8% of those without discontinued within one year. Discontinuation is followed by regain of 60% to 163% of the weight originally lost.

The only relevant evidence is by analogy, from bariatric surgery: after sleeve gastrectomy, higher baseline 25(OH)D predicted reduced weight regain and better type-2 diabetes remission at one year, accounting for 7.5% of the variance in HbA1c.

The plausible mechanism is everything above. Someone who exits GLP-1 therapy with preserved muscle, preserved bone, and preserved activity capacity is in a very different position from someone who lost a third of their weight as lean tissue.

What this does NOT show: this is one surgical cohort extrapolated to a pharmacological one. No study has examined vitamin D status and weight regain after GLP-1 discontinuation. Treat it as a hypothesis worth testing, not a demonstrated benefit.

No RCTs yet for GLP-1 and Vitamin D

There is no randomized trial of vitamin D supplementation in GLP-1 users. Not one, for any of the four outcomes above. The closest is NCT06981936, a registered trial of a comprehensive multivitamin/mineral tablet versus placebo for preventing micronutrient deficiency in GLP-1 users — a multivitamin, not a vitamin D dose-response study.

Every argument on this page is therefore either

(a) mechanistic,
(b) borrowed from ordinary weight loss in obese people, or
(c) observational association between baseline status and outcome.

That borrowing is reasonable — the Lancet authors themselves attribute GLP-1 muscle loss to the magnitude of weight loss rather than the drug — but it is an extrapolation, and readers should know it.

Two differences argue that GLP-1 users need more vitamin D attention than ordinary dieters, not less: the weight loss is faster (more bone and muscle stress per unit time), and fat malabsorption is unique to this drug class.

Strange: GLP users lose vitamin D; regular weight loss users raise vitamin D

Weight loss releases vitamin D that was sequestered in fat tissue. Low-calorie-diet trials show serum 25(OH)D rising 12–13 nmol/L with weight loss.
So a GLP-1 user whose 25(OH)D holds steady through 20% weight loss has actually lost vitamin D — the same body pool is now distributed through a smaller volume.

GLP-1 in VitaminDWiki

Weight loss in VitaminDWiki

Coverage of GLP-1 for weight loss as of July 2026

Medicaid 12 states - had been 16 states in 2025

Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island (will end Oct 2026), Tennessee, Utah, Virginia, Wisconsin.

Medicare $50/month only if meet the clinical criteria: 7/2026 to 12/2027

Employer insurance coverage is dropping: now 20% to 60% (different surveys)

CLAUDE AI

Actions suggested by VitaminDWiki

Best benefit if you raise vitamin D levels BEFORE trying to lose weight, face muscle, etc.
- Raise in 1 week: Take 50,000 IU Vitamin D once to check for rare immediate reaction by body.
  If no reaction (itchy skin), take 50,000 IU daily for a week (350,000 IU total
- Raise in 2 months: take 50,000 IU weekly
- OR raise in 3 months
One pill every two weeks gives you all the vitamin D most adults need
includes data on weekly dosing
More Weight loss if you add Vitamin D and Receptor activators: Berberine, Butrate, etc

Top 10 adverse effects of taking GLP-1 or losing weight

Ranked by a mix of frequency and consequence rather than frequency alone — the merely common ones (nausea) are mild and transient, while the ones that matter most for long-term health are less common but harder to reverse.

1. Lean mass loss. The most underappreciated cost. In the 72-week tirzepatide trial, lean body mass fell 10.9% vs 2.6% on placebo — roughly 25% of total weight lost was lean tissue, and landmark semaglutide and tirzepatide trials reported lean soft tissue losses of about 26–40% of total weight lost. The magnitude has been likened to what a person would normally lose over a decade or more of aging. It appears to be a bystander effect of profound caloric restriction plus absent mechanical stimulus, not a direct catabolic action of the drug — which is why protein above 1.2 g/kg/day spread evenly across meals plus structured resistance training is the standard mitigation.

2. GI effects — nausea, vomiting, diarrhea, constipation, bloating, abdominal pain. In one trial 44.2% reported nausea and 24.8% vomiting; pooled STEP 1–3 data show most events in the first 20 weeks, leading to dose reduction or interruption in ~12.5% and permanent discontinuation in ~4.3%. A systematic review of 39 RCTs confirms this as a class effect.

3. Weight regain on cessation — and it comes back as fat. A meta-analysis of eight RCTs found participants regained 9.69 kg over 48–52 weeks after stopping. Regained weight may disproportionately accumulate as fat, including intramuscular fat infiltration. Combined with #1, repeated cycles ratchet body composition the wrong way.

4. Sarcopenic obesity in older adults. Up to two-thirds discontinue within a year, and weight cycling may produce fat gains alongside muscle losses that aren't regained — a real frailty and fall risk over 60.

5. Bone density loss. Rapid large weight loss reduces mechanical loading and BMD; this is being actively studied alongside the muscle question, and fracture risk in this population isn't yet well characterized.

6. NAION (optic nerve infarct, permanent vision loss). The EMA's safety committee concluded NAION is a "very rare" side effect affecting up to 1 in 10,000 semaglutide users, and mandated labeling updates. The FDA has not added this to US labels. Sudden painless vision loss on waking warrants immediate discontinuation and evaluation.

7. Gallbladder disease. Rapid weight loss plus reduced gallbladder motility → gallstones and cholecystitis. Gallbladder problems have been linked to GLP-1s.

8. Acute kidney injury. Most AKI events are prerenal — dehydration from severe nausea, vomiting, and diarrhea — rather than direct nephrotoxicity, with absolute trial rates under 0.5%. Largely a downstream consequence of #2.

9. Psychiatric effects. EudraVigilance analysis found psychiatric adverse events in 1.18% of reports, with depression, anxiety, and suicidal ideation the signals of concern. Causality remains contested.

10. Nutrient inadequacy. Eating 30–40% less food means 30–40% fewer micronutrients unless intake is deliberately restructured — protein, calcium, iron, B12, and the fat-soluble vitamins (D, K2, A, E) are the usual casualties, and fat-soluble absorption depends on the dietary fat people cut first. This compounds #1 and #5.

Two things that didn't make the list but often appear on others: pancreatitis and pancreatic cancer risk have largely been dispelled by long-term trials, and facial volume loss ("Ozempic face") is cosmetic rather than pathological — a consequence of rapid changes in fat distribution.

Worth noting for framing: items 1, 3, 5, and 10 aren't drug-specific toxicity — any large weight loss, including caloric restriction or bariatric surgery, produces some lean mass loss. What GLP-1s change is the scale and how easily it happens without the behavioral scaffolding that used to accompany it.